Abstract:Inhibition of tumor angiogenesis is an anticancer strategy in which neovasculature is targeted because tumor progression relies on neovascularization. The soluble, truncated form of vascular endothelial growth factor receptor-2 (VEGFR-2), sFLK-1, is a well-known inhibitor of endothelial cells. This kind of soluble receptor retains its high-affinity binding to VEGF, but cannot work with the receptor tyrosine transphosphorylation and activation of downstream signal transduction to induce endothelial proliferation due to the lack of the tyrosine kinase domain. Therefore, we tried to use this sFLK-1 as an inhibitor for malignant tumor gene therapy. In this study we transferred a soluble VEGFR-2 (sFLK-1) from embryo mouse liver by RT-PCR to PA317 cells through retroviral vector (pLXSN) and obtained stable expression. NIH3T3 cells were used for measuring the virus titer. The virus titer in this experiment was 2 x 10(7) CFU/ml. After 7 days of preparing subcutaneous tumor models bearing S180, MCF-7, and B16 cells in mice, respectively, 2 x 10(7) PFU of recombinant retroviruses were injected locally into the tumors the treatment groups. After treatment, the tumor size and weight were significantly smaller than that of control (p < 0.05). After autopsy, the metastasic focus numbers in the treatment groups were also less than control groups. We also measured VEGFR-2 expression in tumor tissues by Western blot to check if sFLK-1 had been integrated into the cells of tumor tissues. Expression in the treatment groups was significantly greater than that of control groups (p < 0.001). Microvessel. density (MVD) and proliferative cell nuclear antigen (PCNA) were investigated to determine whether the Re-sFLK-1 fragment had the ability to inhibit tumor angiogenesis and proliferation in mice bearing S180 and MCF-7 cells. The results showed that MVD and PCNA in the treatment groups were lower than in control groups. There were significant difference between treatment groups and control groups (p < 0.0001). The results indicated that retroviral-mediated sFLK-1 gene therapy in animal tumor models has significant therapeutic effect.

Redirecting full-length FLT1 expression towards its soluble isoform promotes postischemic angiogenesis

FGFR1 SUMOylation Coordinates Endothelial Angiogenic Signaling in Angiogenesis

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications

Gene Cloning of Soluble VEGF Receptor FLT-1 and the Effect of Its Recombinant Protein on Angiogenesis

Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) Pre-Mrna is Important for the Regulation of VEGF Activity

A Novel tRNA-Derived Fragment, tRF<SUP>GlnCTG</SUP>, Regulates Angiogenesis by Targeting Antxr1 mRNA

Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

Efficient fine-tuning of endothelial gene expression by a single Tyrosine to Phenylalanine point mutation in the gene

A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization

[Cloning, Expression of Soluble VEGFR2 Fragment and Its Effect on Tumor Angiogenesis].

Gene Therapeutic Exploration: Retrovirus-Mediated Soluble Vascular Endothelial Growth Factor Receptor-2 (Sflk-1) Inhibits the Tumorigenicity of S180, Mcf-7, and B16 Cells in Vivo

Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide-Mediated Angiogenesis

RNF20-mediated transcriptional pausing and VEGFA splicing orchestrate vessel growth

Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1

Sflt-1 Gene Therapy of Follicular Thyroid Carcinoma

Tnfsf15 Inhibits Vasculogenesis by Regulating Relative Levels of Membrane-Bound and Soluble Isoforms of Vegf Receptor 1

In Vivo Inhibition of Tumor Angiogenesis by A Soluble Vegfr-2 Fragment

Effect of Soluble Vascular Endothelial Growth Factor( VEGF) Receptor Gene (sflt- 1) and Antisense VEGF Nucleotide on Neovascularization

Lentivirus-Mediated Sflt-1 Gene Fragment Transfer Suppresses Retinal Neovascularization